Investors > News Releases
Nov 11, 2019
Myriad’s Prequel™ Prenatal Screen Demonstrates High Performance Across All Fetal-Fraction Levels in Women Undergoing Noninvasive Prenatal Screening
Pipeline
Nov 09, 2019
New Studies Demonstrate the Predictive Value of the Vectra® Test in People Diagnosed with Rheumatoid Arthritis
Pipeline
Nov 07, 2019
Myriad Genetics to Present at the 2019 Stephens Nashville Investment Conference
Corporate
Nov 06, 2019
GeneSight® Psychotropic Test Improved Clinical Outcomes for People with Depression Who Were Taking Medications with Gene-Drug Interactions
Products
Nov 04, 2019
Myriad Genetics Reports Fiscal First-Quarter 2020 Financial Results
Financial
Nov 01, 2019
Myriad Genetics Announces Multiple Presentations at the 2019 American College of Rheumatology Annual Meeting
Products
Oct 30, 2019
Myriad to Announce Fiscal First-Quarter 2020 Financial Results on November 4, 2019
Corporate
Oct 28, 2019
Myriad Genetics to Present Seven Studies at the 2019 National Society of Genetic Counselors Annual Meeting
Products
Oct 23, 2019
FDA Approves Myriad’s myChoice® CDx Test to Help Identify Women Eligible for Treatment with Zejula® in Late-line Ovarian Cancer
Products
Oct 21, 2019
Dr. Mark H. Pollack named Chief Medical Officer for Myriad Neuroscience
Corporate
Oct 08, 2019
Myriad Genetics to Present Five Studies at the 2019 American Society of Human Genetics Annual Meeting
Pipeline
Sep 25, 2019
Myriad Genetics Expands Board of Directors with Two Additional Members
Corporate
Sep 16, 2019
Myriad Announces Research Collaboration with University of Leeds
Pipeline
Sep 05, 2019
Prolaris® Test Identifies Men with Prostate Cancer Who Can Safely Defer Treatment
Pipeline
Aug 30, 2019
Myriad Genetics to Present at the 2019 Morgan Stanley Global Healthcare Conference
Corporate